A_weekly_cisplatin-based_induction_regimen_for_extensive_non-small_cell_lung_cancer._A_Southwest_Oncology_Group_study._The_purpose_of_this_Phase_II_pilot_study_was_to_determine_whether_a_dose-intensive_regimen_of_weekly_cisplatin_combined_with_other_active_non-cross-resistant_agents_would_improve_the_response_rate_and_survival_time_of_patients_with_extensive_non-small_cell_lung_cancer._Patients_received_cisplatin_(50_mg/m2/wk)_on_days_1,_8,_15,_22,_36,_43,_50,_and_57_combined_with_mitomycin_C_(8_mg/m2)_on_days_1_and_36,_vinblastine_(3_mg/m2)_on_days_8_and_43,_and_5-fluorouracil_(5-FU)_(1_g/m2)_by_continuous_infusion_over_24_hours_on_days_15_and_50._Responding_patients_received_consolidation_therapy_with_cisplatin_and_etoposide_(VP-16)._Of_82_registered_patients,_80_were_eligible_and_77_were_evaluable_for_response._The_overall_response_rate_was_23%_with_1_patient_achieving_a_complete_response_(CR)_and_17_patients_achieving_a_partial_response_(PR)._The_median_survival_time_was_4.6_months._The_toxicity_profile_was_not_different_from_that_described_for_standard-dose_regimens._Although_this_regimen_does_not_offer_any_benefit_over_standard-dose_cisplatin_regimens_for_patients_with_extensive_non-small_lung_cancer,_the_weekly_schedule_permits_a_dose-intensive_regimen_with_acceptable_toxicity_for_tumors_that_may_benefit_from_this_approach.